LYRA

Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, March 21, 2024
Research, LYRA, Common, Bronchitis, Disease, MF, New Drug Application, COVID-19, Patient, Smell, Network congestion, CRS, United, Nasal cavity, Pharmacotherapy, Investment, Clinical trial, Therapy, Safety, Sinusitis, ESS, FDA, Food, Pharmaceutical industry

WATERTOWN, Mass., March 21, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory nasal inserts for the treatment of chronic rhinosinusitis (CRS), today reported its financial results for the fourth quarter and full year ended December 31, 2023 and provided a corporate update.  

Key Points: 
  • WATERTOWN, Mass., March 21, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory nasal inserts for the treatment of chronic rhinosinusitis (CRS), today reported its financial results for the fourth quarter and full year ended December 31, 2023 and provided a corporate update.
  • LYR-220, a larger insert, is designed for CRS patients whose nasal cavity is enlarged due to previous ESS.
  • Cash, cash equivalents and short-term investments were $102.8 million as of December 31, 2023, compared to $102.6 million as of September 30, 2023.
  • The Company recorded an impairment charge of $1.6 million related to long-lived assets for the year ended December 31, 2023.

Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, March 1, 2024
LYRA, Compensated emancipation, Therapy, Sinusitis, CRS, Employment

WATERTOWN, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory nasal inserts for the treatment of chronic rhinosinusitis (CRS), today announced that it has granted non-qualified stock options to purchase a total of 119,200 shares of Lyra common stock to 18 new non-executive employees as an inducement material to their acceptance of employment with Lyra.

Key Points: 
  • WATERTOWN, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory nasal inserts for the treatment of chronic rhinosinusitis (CRS), today announced that it has granted non-qualified stock options to purchase a total of 119,200 shares of Lyra common stock to 18 new non-executive employees as an inducement material to their acceptance of employment with Lyra.
  • The employment inducement awards were approved by Lyra’s independent directors serving on its Compensation Committee and granted under the Company’s 2022 Inducement Award Plan, as amended, and related form of stock option agreement in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The inducement plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Lyra, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with Lyra, pursuant to Nasdaq Listing Rule 5635(c)(4).
  • Each option carries a ten-year term and an exercise price of $5.48 per share, which was the closing price of Lyra’s common stock on February 28, 2024, the date of grant, and vests over a four-year period as follows: 25% of the option vests on the one-year anniversary of the applicable employee’s start date and an additional 1/48th of the option vests in equal monthly installments over the following three years, subject to the employee’s continued service through each vesting date.

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Lyra Therapeutics, Inc. (NASDAQ: LYRA) and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, November 11, 2023
Acquisition, LYRA, Lyra

PHILADELPHIA, Nov. 11, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Lyra Therapeutics, Inc. (NASDAQ: LYRA) (“Lyra”) on behalf of the company’s investors.

Key Points: 
  • PHILADELPHIA, Nov. 11, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Lyra Therapeutics, Inc. (NASDAQ: LYRA) (“Lyra”) on behalf of the company’s investors.
  • Lyra stockholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq.
  • Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation on a contingent basis.
  • For additional information about Kaskela Law LLC please visit www.kaskelalaw.com .

Lyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, November 7, 2023
Mometasone, Research, Food, Public expenditure, Polyp, Bronchitis, Regulation of tobacco by the U.S. Food and Drug Administration, Network congestion, Sinusitis, COVID-19, Common, New Drug Application, CT, Depreciation, Safety, CRS, MF, Therapy, Investment, Patient, LYRA, Nursing, Pharmaceutical industry, Medical device, Birth control, Lyra

WATERTOWN, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting anti-inflammatory therapies for the localized treatment of chronic rhinosinusitis (CRS), today reported its financial results for the third quarter ended September 30, 2023 and provided a corporate update.  

Key Points: 
  • The Company plans to submit results of the BEACON study for presentation at an upcoming medical meeting.
  • In August 2023, Lyra announced completion of enrollment in the pivotal Phase 3 ENLIGHTEN I clinical trial.
  • Cash, cash equivalents and short-term investments as of September 30, 2023 were $102.6 million, compared with $116.2 million at June 30, 2023.
  • Net loss for the quarter ended September 30, 2023 was $15.7 million compared to $14.8 million for the same period in 2022.

Lyra Therapeutics to Participate in Upcoming Investor Conferences

Retrieved on: 
Tuesday, November 7, 2023
CRS, Sinusitis, Therapy, Conference, LYRA, Pharmaceutical industry

WATERTOWN, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics , Inc. (Nasdaq: LYRA), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced that Maria Palasis, Ph.D., President and Chief Executive Officer, will participate in the following investor conferences in November:

Key Points: 
  • WATERTOWN, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics , Inc. (Nasdaq: LYRA), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced that Maria Palasis, Ph.D., President and Chief Executive Officer, will participate in the following investor conferences in November:
    Jefferies London Healthcare Conference 2023 – Fireside chat on Thursday, November 16th at 1:30 p.m. GMT
    Piper Sandler 35th Annual Healthcare Conference – Presentation on Wednesday, November 29th at 9:30 a.m.
  • ET
    Live webcast of the presentations will be available on the Investor Relations section of the Company's website at investors.lyratherapeutics.com .
  • Replays of the webcasts will be available for 30 days following the presentation.

INVESTOR ALERT: Abbott Cooper PLLC Announces Investigation into Lyra Therapeutics, Inc.; Urges Lyra Stockholders to Contact Abbott Cooper Regarding Their Legal Rights

Retrieved on: 
Saturday, November 4, 2023
LYRA, Lyra

STAMFORD, Conn., Nov. 04, 2023 (GLOBE NEWSWIRE) -- Abbott Cooper PLLC is investigating Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”) on behalf of the Company’s investors.

Key Points: 
  • STAMFORD, Conn., Nov. 04, 2023 (GLOBE NEWSWIRE) -- Abbott Cooper PLLC is investigating Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”) on behalf of the Company’s investors.
  • Lyra stockholders are encouraged to contact Abbott Cooper PLLC by calling (475) 333-0674, emailing [email protected] or by filling out a contact from on our website at www.abbottlawyer.com for additional information about this investigation as well as their legal rights and options.
  • Abbott Cooper PLLC is dedicated to shareholders’ rights and empowering shareholders through strategic counsel and legal advocacy.
  • For additional information about Abbott Cooper PLLC, please visit www.abbottlawyer.com .

Lyra Therapeutics Announces Appointment of Ronan O’Brien as Chief Legal Officer

Retrieved on: 
Monday, October 16, 2023
Boston University, General counsel, LYRA, Employment, Biotechnology, Therapy, CRS, Sinusitis, Pharmaceutical industry, Lyra

WATERTOWN, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (“CRS”), today announced the appointment of Ronan O’Brien, as Chief Legal Officer, effective October 16, 2023.

Key Points: 
  • WATERTOWN, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (“CRS”), today announced the appointment of Ronan O’Brien, as Chief Legal Officer, effective October 16, 2023.
  • “We are pleased to welcome Mr. O’Brien to Lyra,” said Maria Palasis, Ph.D., Chief Executive Officer of Lyra.
  • Most recently Mr. O’Brien served as General Counsel, Chief Compliance Officer & Secretary of Pear Therapeutics, Inc., an innovative medical device company, which launched three commercial products.
  • The inducement grant is subject to the terms and conditions of the award agreement covering the stock option grant and the 2022 Inducement Plan.

Lyra Therapeutics Announces Positive Topline Results from BEACON Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis (CRS) in Patients with Prior Ethmoid Sinus Surgery

Retrieved on: 
Tuesday, September 12, 2023
UNC School of Medicine, ENT, Bronchitis, ARS, CRS, Conference call, Telephone, COVID-19, Quality of life, Allergy, MF, LYRA, Trial of the century, Sinusitis, Network congestion, Phase 3, MD, Patient, Physician, Division, Common, Annual general meeting, Webcast, Lyra, Therapy, Polyp, Mometasone, Pharmaceutical industry, Birth control, Tissue paper, Conference, Medicine

WATERTOWN, Mass., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics , Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced positive topline results from the BEACON Phase 2 clinical study of LYR-220 in adult patients with CRS, with and without polyps, who have had prior ethmoid sinus surgery.

Key Points: 
  • WATERTOWN, Mass., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics , Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced positive topline results from the BEACON Phase 2 clinical study of LYR-220 in adult patients with CRS, with and without polyps, who have had prior ethmoid sinus surgery.
  • The study met its primary safety endpoint, with no serious adverse events observed.
  • Topline results from the BEACON study of LYR-220 will be presented at the American Rhinologic Society (ARS) 69th Annual Meeting on September 30, 2023, in Nashville, TN.
  • ET to discuss the topline results of the BEACON study.

Lyra Therapeutics to Participate in Upcoming Investor Conferences

Retrieved on: 
Wednesday, September 6, 2023
Sinusitis, Therapy, Conference, CRS, LYRA, Pharmaceutical industry

WATERTOWN, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics , Inc. (Nasdaq: LYRA), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced that Maria Palasis, Ph.D., President and Chief Executive Officer, will participate in the following investor conferences in September:

Key Points: 
  • WATERTOWN, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics , Inc. (Nasdaq: LYRA), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced that Maria Palasis, Ph.D., President and Chief Executive Officer, will participate in the following investor conferences in September:
    H.C. Wainwright 25th Annual Global Investment Conference – Fireside chat on Wednesday, September 13th at 2:00 p.m.
  • ET
    Cantor Global Healthcare Conference 2023 – Fireside chat on Tuesday, September 26th at 4:20 p.m.
  • ET
    Live webcast of the presentations will be available on the Investor Relations section of the Company's website at investors.lyratherapeutics.com .
  • Replays of the webcasts will be available for 30 days following the presentation.

Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN I Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis

Retrieved on: 
Tuesday, August 29, 2023
Sinusitis, Lyra, Therapy, MD, Patient, MF, CRS, LYRA, Mometasone, Pharmaceutical industry, Nursing

WATERTOWN, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics , Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting anti-inflammatory therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced that the pivotal Phase 3 ENLIGHTEN I clinical trial of LYR-210 in adult patients with CRS who have not had prior ethmoid sinus surgery, is fully enrolled.

Key Points: 
  • WATERTOWN, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics , Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting anti-inflammatory therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced that the pivotal Phase 3 ENLIGHTEN I clinical trial of LYR-210 in adult patients with CRS who have not had prior ethmoid sinus surgery, is fully enrolled.
  • LYR-210 is a bioresorbable nasal implant designed to deliver six months of continuous anti-inflammatory medication (mometasone furoate; MF) to the sinonasal passages for the treatment of CRS.
  • Topline results from ENLIGHTEN I are expected in the first half of 2024 as planned.
  • “We are pleased to have fully enrolled the first of our two pivotal trials of LYR-210 in CRS patients,” said Richard Nieman, MD, Chief Medical Officer of Lyra Therapeutics.